
'DHL has completely underestimated the resolve of our membership': UNIFOR President
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
a minute ago
- Globe and Mail
Thermo Fisher Q2 Earnings & Revenues Beat, Stock Up in Pre-Market
Thermo Fisher Scientific Inc. 's TMO second-quarter 2025 adjusted earnings per share (EPS) of $5.36 beat the Zacks Consensus Estimate by 2.7%. However, the figure decreased 0.2% year over year. The adjusted number excludes certain expenses, including asset amortization costs and certain restructuring costs. GAAP EPS was $4.28, up 6% on a year-over-year basis. Following the earnings announcement, shares of TMO rose 7.7% in pre-market trading today. TMO's Q2 Revenues in Detail Revenues in the quarter increased 2.9% year over year to $10.85 billion. Moreover, the top line surpassed the Zacks Consensus Estimate by 1.9%. Organic revenues in the reported quarter increased 2% year over year. Thermo Fisher's Segmental Analysis Thermo Fisher operates under four business segments, as discussed below: Life Sciences Solutions Revenues in the Life Sciences Solutions segment (23% of total revenues) increased 6.1% year over year to $2.50 billion. The number surpassed our model's estimate of $2.37 billion. Analytical Instruments Revenues in this segment (15.9%) declined 3% year over year to $1.73 billion. The figure missed our model's estimate of $1.84 billion. Specialty Diagnostics Revenues in the Specialty Diagnostics segment (10.4%) increased 1.5% year over year to $1.13 billion. The number missed our model's prediction of $1.15 billion. Laboratory Products and Biopharma Services Revenues in this segment (55.2%) rose 4.1% year over year to $5.99 billion. Our model's estimate was $5.71 billion. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) TMO's Margin Performance Gross margin of 41.2% in the second quarter contracted 83 basis points (bps) year over year due to a 4.4% increase in the cost of revenues. In the quarter, selling, general and administrative expenses rose 5.4% to $1.78 billion. Research and development expenses increased 3.8% to $352 million. The adjusted operating margin in the quarter was 21.6%, reflecting a contraction of 124 bps. Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise TMO's Financial Position The company ended the second quarter of 2025 with cash and cash equivalents and short-term investments of $6.39 billion compared with $5.95 billion at the end of the first quarter of 2025. Cumulative net cash from operating activities at the end of the second quarter was $2.12 billion compared with $3.21 billion a year ago. Thermo Fisher has a consistent dividend-paying history, with the five-year annualized dividend growth of 14.86%. Our Take on Thermo Fisher Stock Thermo Fisher exited the second quarter of 2025 with better-than-expected results, wherein both earnings and revenues beat the respective estimates. Barring the Analytical Instruments segment, all other business segments reported growth during the quarter. However, contraction of both margins in the quarter was discouraging. The company will provide its 2025 guidance on the earnings call today. During the second quarter, the company advanced in its growth strategy by launching a range of next-generation, high-impact, innovative instruments, including the Thermo Scientific Orbitrap Astral Zoom mass spectrometer, the Thermo Scientific Orbitrap™ Excedion Pro mass spectrometer and the Thermo Scientific Krios 5 Cryo-TEM. These instruments help researchers deepen the understanding of complex diseases, advance precision medicine and enable the development of new therapies. In addition, TMO expanded the DynaDrive single-use bioreactor portfolio for drug production to include a new first-of-its-kind bench-scale system, enabling meaningful workflow efficiencies and seamless scale-up from the bench to commercialization. All these developments translated into meaningful commercial wins for the company in the second quarter, which is encouraging. TMO's Zacks Rank & Key Picks Thermo Fisher currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Veeva Systems VEEV and Boston Scientific BSX. Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, posted first-quarter 2025 adjusted EPS of $1.81, which exceeded the Zacks Consensus Estimate by 5.9%. Revenues of $2.25 billion surpassed the Zacks Consensus Estimate by 3.3%. You can see the complete list of today's Zacks #1 Rank stocks here. ISRG has an estimated long-term earnings growth rate of 15.1% compared with the industry's 14.4%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.6%. Veeva Systems, currently carrying a Zacks Rank #2 (Buy), reported first-quarter fiscal 2026 adjusted EPS of $1.97, which surpassed the Zacks Consensus Estimate by 13.2%. Revenues of $759 million beat the consensus mark by 4.3%. VEEV has an estimated long-term earnings growth rate of 23.3% compared with the industry's 19.1%. The company beat on earnings in each of the trailing four quarters, the average surprise being 10%. Boston Scientific, carrying a Zacks Rank #2 at present, reported a first-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 0.1%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 20.9%. BSX has a long-term earnings growth rate of 13.2% compared with the industry's 13.9%. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Boston Scientific Corporation (BSX): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Veeva Systems Inc. (VEEV): Free Stock Analysis Report


CTV News
a minute ago
- CTV News
‘Dream team of cows': CATTLEytics wants to redefine farm data with AI
A Hamilton-based company aims to empower farmers with tools to make informed decisions by using artificial intelligence (AI) across all aspects of their operations. CATTLEytics offers data-driven proprietary software tailored to dairy and livestock farmers to assist with breeding decisions, targeted animal health protocols, optimal management decisions and even staff scheduling and task management. 'If you've ever seen the movie Moneyball, you're optimizing a baseball team. We want to do that for dairy cows. You're making your dream team of cows with the data that you have, so next season, you're going to have the best herd,' Shari van de Pol, the company's chief executive officer, told BNN Bloomberg in a Tuesday interview. The company leverages digital twin simulations, streamlined protocols and custom analytics to enable producers to enhance efficiency, profitability and sustainability without expanding resources. She said farmers save about one to two hours a day with analytics. 'The concept with software these days is that we really try to create a digital version of everything that exists on a dairy (farm) in order to better connect with all the different interactions that would happen on that dairy (farm),' said van de Pol. 'For instance, if there's a treatment plan, we would have a digital version of the treatment plan. If there's a drug to be used, we would have a digital version of the drug. If, for instance, there's yes, a calf born, we'll have a digital version of that calf. That helps us really connect all those different interactions so we can better model what's happening on our dairy (farms).' Farmers have used technology for many years. In fact, Canada was recognized as one of the global leaders in the agricultural technology industry with precision agriculture, according to Northbridge Consultants. The market value of precision agriculture in Canada reached $870 million in 2021. Precision agriculture refers to a suite of farm management technologies, as well as data and analytics used to increase efficiency, production, and sustainability, according to CIBC Thought Leadership. Tools include GPS, sensors, robotics, drones, autonomous vehicles, and software. van de Pol wants to build on top of advancements made on farms. 'In the 90s, there was precision agriculture then we moved on to have pedometers, because, you might know this, but most cows actually wear kind of like a Fitbit, so that you know how many steps they take,' said van de Pol. 'We moved on into the AI age, but we need to continue, especially in Canada, all of these efficiencies in order to be able to provide the amazing, nutritious food that we provide for everybody every day.' van de Pol grew up in a rural community before beginning her career in computer engineering and data analytics at large multinational companies. She later became a large-animal veterinarian. She created the company combining her passion for technology and veterinary medicine. Her company employees about 12 to 14 people depending on the season to help farmers run a farm while understanding the challenges farmers face. 'In order to run a farm like the actual people, they have to understand animal biology,' said van de Pol. 'They have to run a business. They have to be able to service equipment and run equipment. There's so much knowledge to this but then the workers themselves too, have to understand everything tied to animal husbandry.' Farmers must also abide by strict protocols. Dairy Farmers of Canada, a national policy, lobbying, and promotional organization representing Canadian dairy producers, developed proAction, a national quality assurance program for the Canadian dairy sector. The program is mandated on all Canadian dairy farms. 'There's really strict protocols,' said van de Pol. 'In Canada, we have something called proAction that is kind of like the way that there's a food inspection, we have that for dairy farms. There's so much knowledge that goes into running one of these operations, it's probably one of the most difficult types of farming out there'.


Globe and Mail
a minute ago
- Globe and Mail
D-Wave Quantum (NYSE: QBTS) Reports Strong Expectations for Quantum Computing-Based Optimization
D-Wave Quantum (NYSE: QBTS) ('D-Wave'), a leader in quantum computing systems, software, and services, released findings from a survey conducted with Wakefield Research showing rising enterprise interest in quantum optimization. The survey polled 400 business leaders, defined as logistics or operational managers and decision-makers who make decisions about optimization in their line-of-business. Of the business leaders surveyed who have implemented quantum optimization or plan to do so within the next two years, 46% expect return on investment (ROI) between $1 and $5 million within a year, while 27% anticipate an ROI exceeding $5 million within that time. The report highlights that 81% of respondents believe that they have reached the limits of benefits they can achieve from optimization on classical computers, with 53% planning to adopt quantum in workflows. Key target areas include supply chain, logistics, and manufacturing. CEO Dr. Alan Baratz said the survey results underscore the immediate business relevance of annealing quantum solutions. To view the full press release, visit About D-Wave Quantum Inc. D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world's first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our quantum computers, the world's largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our quantum systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we're shaping the quantum-driven industrial and societal advancements of tomorrow: Forward Looking Statements Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Corporate Communications